Chimeric flagellin as the self-adjuvanting antigen for the activation of immune response against Helicobacter pylori

Vaccine

Volumn 30, Issue 40, 2012, Pages 5856-5863

  Mori, Jerneja ^a   Vranac, Tanja ^c   Smrekar, Boštjan ^c   Černilec, Maja ^c   Šerbec, Vladka Čurin ^c,d   Horvat, Simon ^a,d   Ihan, Alojz ^e   Benčina, Mojca ^a,b   Jerala, Roman ^a,b,d  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b Centre of Excellence   (Slovenia)

^c BLOOD TRANSFUSION CENTRE OF SLOVENIA   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Adjuvant; Chimeric protein; Flagellin; Helicobacter pylori; Innate immunity; Toll like receptor 5

Indexed keywords

CHIMERIC FLAGELLIN; CHIMERIC PROTEIN; FLAGELLIN; HELICOBACTER PYLORI VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL IMMUNITY; CONTROLLED STUDY; HELICOBACTER INFECTION; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; ESCHERICHIA COLI; FLAGELLIN; HEK293 CELLS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNITY, INNATE; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; TOLL-LIKE RECEPTOR 5;

EID: 84864822911     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.011     Document Type: Article

References (40)

1. Peterson W.L. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991, 324(April (15)):1043-1048.
2. IARC IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Helicobacter pylori: Views and Expert Opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans 1994.
3. Dunn B.E., Cohen H., Blaser M.J. Helicobacter pylori. Clin Microbiol Rev 1997, 10(October (4)):720-741.
4. Watanabe T., Tada M., Nagai H., Sasaki S., Nakao M. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998, 115(September (3)):642-648.
5. Marshall B.J. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am 1993, 22(March (1)):183-198.
6. Lee S.K., Stack A., Katzowitsch E., Aizawa S.I., Suerbaum S., Josenhans C. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003, 5(December (15)):1345-1356.
7. Gewirtz A.T., Yu Y., Krishna U.S., Israel D.A., Lyons S.L., Peek R.M. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004, 189(May (10)):1914-1920.
8. Andersen-Nissen E., Smith K.D., Strobe K.L., Barrett S.L., Cookson B.T., Logan S.M., et al. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc Natl Acad Sci U S A 2005, 102(June (26)):9247-9252.
9. Beatson S.A., Minamino T., Pallen M.J. Variation in bacterial flagellins: from sequence to structure. Trends Microbiol 2006, 14(April (4)):151-155.
10. Yonekura K., Maki-Yonekura S., Namba K. Complete atomic model of the bacterial flagellar filament by electron cryomicroscopy. Nature 2003, 424(August (6949)):643-650.
11. Galkin V.E., Yu X., Bielnicki J., Heuser J., Ewing C.P., Guerry P., et al. Divergence of quaternary structures among bacterial flagellar filaments. Science 2008, 320(April (5874)):382-385.
12. Samatey F.A., Imada K., Nagashima S., Vonderviszt F., Kumasaka T., Yamamoto M., et al. Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling. Nature 2001, 410(March (6826)):331-337.
13. Steiner T.S., Nataro J.P., Poteet-Smith C.E., Smith J.A., Guerrant R.L. Enteroaggregative Escherichia coli expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. J Clin Invest 2000, 105(June (12)):1769-1777.
14. Nempont C., Cayet D., Rumbo M., Bompard C., Villeret V., Sirard J.C. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 2008, 181(August (3)):2036-2043.
15. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(January (2)):201-214.
16. Sanders C.J., Yu Y., Moore D.A., Williams I.R., Gewirtz A.T. Humoral immune response to flagellin requires T cells and activation of innate immunity. J Immunol 2006, 177(September (5)):2810-2818.
17. de Zoete M.R., Keestra A.M., Wagenaar J.A., van Putten J.P. Reconstitution of a functional Toll-like receptor 5 binding site in Campylobacter jejuni flagellin. J Biol Chem 2010, 285(April (16)):12149-12158.
18. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25(January (4)):763-775.
19. Smythies L.E., Waites K.B., Lindsey J.R., Harris P.R., Ghiara P., Smith P.D. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000, 165(July (2)):1022-1029.
20. Delaney K.N., Phipps J.P., Johnson J.B., Mizel S.B. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol 2010, 23(April (2)):201-210.
21. Mizel S.B., Graff A.H., Sriranganathan N., Ervin S., Lees C.J., Lively M.O., et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 2009, 16(January (1)):21-28.
22. Mizel S.B., Bates J.T. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 2010, 185(November (10)):5677-5682.
23. Song L., Zhang Y., Yun N.E., Poussard A.L., Smith J.N., Smith J.K., et al. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27(42):5875-5884.
24. Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011, 17(8):996-1002.
25. Vogel F.R. Immunologic adjuvants for modern vaccine formulations. Ann N Y Acad Sci 1995, 754(May):153-160.
26. Golding B., Scott D.E. Vaccine strategies: targeting helper T cell responses. Ann N Y Acad Sci 1995, 754(May):126-137.
27. Pino O., Martin M., Michalek S.M. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar typhimurium to potentiate mucosal and systemic responses. Infect Immun 2005, 73(October (10)):6763-6770.
28. Cunningham A.F., Khan M., Ball J., Toellner K.M., Serre K., Mohr E., et al. Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol 2004, 34(November (11)):2986-2995.
29. Agrawal S., Agrawal A., Doughty B., Gerwitz A., Blenis J., Van Dyke T., et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003, 171(November (10)):4984-4989.
30. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2(October (10)):947-950.
31. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453(June (7198)):1122-1126.
32. Kool M., Pétrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181(September (6)):3755-3759.
33. Li H., Willingham S.B., Ting J.P., Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008, 181(July (1)):17-21.
34. Kuroda E., Ishii K.J., Uematsu S., Ohata K., Coban C., Akira S., et al. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011, 34(April (4)):514-526.
35. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17(April (4)):479-487.
36. Weltzin R., Kleanthous H., Guirakhoo F., Monath T.P., Lee C.K. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 1997, 15(March (4)):370-376.
37. Pickett T.E., Pasetti M.F., Galen J.E., Sztein M.B., Levine M.M. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun 2000, 68(January (1)):205-213.
38. Londoño-Arcila P., Freeman D., Kleanthous H., O'Dowd A.M., Lewis S., Turner A.K., et al. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun 2002, 70(September (9)):5096-5106.
39. Lee C.K., Soike K., Giannasca P., Hill J., Weltzin R., Kleanthous H., et al. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine 1999, 17(August (23-24)):3072-3082.
40. Srivastava I., Goodsell A., Zhou F., Sun Y., Burke B., Barnett S., et al. Dynamics of acute and memory mucosal and systemic immune responses against HIV-1 envelope following immunizations through single or combinations of mucosal and systemic routes. Vaccine 2008, 26(May (22)):2796-2806.